Seems like a positive announcement.
Quote:
"AdAlta conducted a study of AD-214 administered intravenously at various doses and
dose intervals in the bleomycin mouse model. Treatment with AD-214 at 1-30mg/kg every
second day and 10-30mg/kg every fourth day resulted in a statistically significant reduction
in the Ashcroft Score of bleomycin-treated mice compared with mice receiving bleomycin
alone (Figure 1). In contrast, treatment with two drugs currently approved for IPF –
pirfenidone and nintedanib – did not result in a statistically significant reduction in Ashcroft
score under test conditions."
Looks like we have a clear winner here. Bring on the human trials.
- Forums
- ASX - By Stock
- 1AD
- Ann: AD-214 effective in gold standard pre-clinical animal model
Ann: AD-214 effective in gold standard pre-clinical animal model, page-3
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add 1AD (ASX) to my watchlist
(20min delay)
|
|||||
Last
2.3¢ |
Change
-0.001(4.17%) |
Mkt cap ! $12.79M |
Open | High | Low | Value | Volume |
2.5¢ | 2.5¢ | 2.3¢ | $2.466K | 102.7K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
4 | 635388 | 2.3¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
2.5¢ | 302763 | 4 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
4 | 635388 | 0.023 |
1 | 10000 | 0.022 |
4 | 1327615 | 0.021 |
5 | 951797 | 0.020 |
2 | 1028500 | 0.019 |
Price($) | Vol. | No. |
---|---|---|
0.025 | 302763 | 4 |
0.027 | 370833 | 1 |
0.028 | 22049 | 1 |
0.029 | 335889 | 2 |
0.030 | 600000 | 2 |
Last trade - 15.02pm 15/05/2024 (20 minute delay) ? |
Featured News
1AD (ASX) Chart |
The Watchlist
SS1
SUN SILVER LIMITED
Gerard O’Donovan, Executive Director
Gerard O’Donovan
Executive Director
SPONSORED BY The Market Online